In this article
FDA Approval for ALK-Positive Inflammatory Myofibroblastic Tumors
July 2022: Crizotinib (Xalkori, Pfizer Inc.) was granted approval by the Food and Drug Administration (FDA) for the treatment of adult and paediatric patients 1 year of age and older who were diagnosed with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumours that were positive for ALK (IMT).
Clinical Trial Evaluation for Pediatric and Adult Patients
Both the safety and efficacy of crizotinib were evaluated in two separate multicenter, single-arm, open-label trials. These trials included both paediatric and adult patients with unresectable, recurrent, or refractory ALK-positive IMT. The paediatric patients participated in trial ADVL0912 (NCT00939770), while the adult patients participated in trial A8081013 (NCT01121588).
Efficacy and Objective Response Rate Results
The objective response rate was the primary indicator of efficacy that was measured in these trials (ORR). An objective response was found in 12 out of the 14 paediatric patients (which corresponds to an 86% success rate with a 95% confidence interval ranging from 57% to 98%) when the patients were evaluated by an independent review committee. Five out of the seven adult patients exhibited objective signs of improvement.
Common Adverse Reactions and Side Effects
The symptoms of vomiting, nausea, diarrhoea, abdominal pain, rash, vision disorder, upper respiratory tract infection, cough, pyrexia, musculoskeletal pain, fatigue, edoema, and constipation were the most common adverse reactions (35 percent) in paediatric patients. In adult patients, vision disorders, nausea, and edoema were the adverse reactions that occurred more frequently than thirty-five percent of the time.
Recommended Dosage for Adults and Pediatrics
Crizotinib should be administered orally twice daily at a dose of 250 milligrammes (mg) in adult patients until the disease worsens or unacceptable toxicity is reached. Orally administering 280 mg/m2 twice daily is the paediatric dose that is recommended until disease progression or unacceptable toxicity occurs.
View full prescribing information for Xalkori.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.